Amyloid Hypothesis Dominance Leaves Dementia Research With Sparse Clinical Wins
Coverage of dementia research highlights persistent explanatory gaps after 120 years. Evidence from RCTs and large cohorts shows limited translation from molecular targets to clinical outcomes. Future studies must prioritize pragmatic endpoints and diverse populations.
The 2026 New York Times overview frames dementia as an enduring mystery since Alzheimer’s 1906 description, yet it understates the pattern of phase 3 failures that followed the 1990s amyloid-cascade model. Observational cohorts such as the Rotterdam Study linked vascular risk factors to incidence, while interventional trials targeting plaques repeatedly missed primary cognitive endpoints. Recent conditional approvals rest on surrogate biomarker changes rather than sustained functional benefit.
FDA: By 2028, no new dementia drug will show greater than 25 percent slowing of CDR-SB decline in a phase 3 trial with 500-plus participants.
Sources (2)
- [1]Primary Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2212948)
- [2]Supporting Source(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-3/fulltext)